Comparison between HSCT, CRTT, and control cohorts at baseline
. | HSCT (n = 10) . | CRTT (n = 20) . | Control (n = 20) . |
---|---|---|---|
Median age, y (IQR) | 11.6 (9.5-16.7) | 13.1 (10.1-18.1) | 11.3 (7.8-14.2) |
Sex, n (% female) | 4 (40) | 13 (65) | 7 (35) |
Median Hb, g/dL (IQR) | 9.1 (7.5-10.1) | 9.1 (8.8-9.8) | NA |
Median Hb S, % (IQR) | 45.75 (35.9-74.2) | 37.4 (29.7-47.5) | NA |
Presence of infarction, n (%) | 8 (80) | 18 (90) | NA |
Cerebral vasculopathy, n (%) | 1 (10) | 4 (20) | NA |
Abnormal TCD, n (%) | 3 (30) | 6 (30) | NA |
Median whole-brain CBF, mL/100 g per min (IQR)∗ | 93.5 (75.9-109.9) | 86.8 (73.3-103.4) | 69.8 (56.0-80.0) |
Median whole-brain OEF, % (IQR)† | 36.8 (34.3-42.2) | 35.3 (32.7-38.6) | 30.9 (27.5-31.9) |
. | HSCT (n = 10) . | CRTT (n = 20) . | Control (n = 20) . |
---|---|---|---|
Median age, y (IQR) | 11.6 (9.5-16.7) | 13.1 (10.1-18.1) | 11.3 (7.8-14.2) |
Sex, n (% female) | 4 (40) | 13 (65) | 7 (35) |
Median Hb, g/dL (IQR) | 9.1 (7.5-10.1) | 9.1 (8.8-9.8) | NA |
Median Hb S, % (IQR) | 45.75 (35.9-74.2) | 37.4 (29.7-47.5) | NA |
Presence of infarction, n (%) | 8 (80) | 18 (90) | NA |
Cerebral vasculopathy, n (%) | 1 (10) | 4 (20) | NA |
Abnormal TCD, n (%) | 3 (30) | 6 (30) | NA |
Median whole-brain CBF, mL/100 g per min (IQR)∗ | 93.5 (75.9-109.9) | 86.8 (73.3-103.4) | 69.8 (56.0-80.0) |
Median whole-brain OEF, % (IQR)† | 36.8 (34.3-42.2) | 35.3 (32.7-38.6) | 30.9 (27.5-31.9) |
All other comparisons are not significant.
IQR, interquartile range; NA, not applicable.
Kruskal-Wallis test P = .001; HSCT vs CRTT not significant (P = .811), HSCT vs control (P = .023), CRTT vs control (P = .003) (Dwass-Steel-Critchlow-Flinger post hoc pairwise P values adjusted for multiple comparisons).
Kruskal-Wallis test P < .001; HSCT vs CRTT not significant (P = .600), HSCT vs control (P = .010), CRTT vs control (P =.001) (Dwass-Steel-Critchlow-Flinger post hoc pairwise P values adjusted for multiple comparisons).